EXTON, PA — Immunome, Inc. (Nasdaq: IMNM), a leading biotech firm specializing in cancer therapies, recently announced its plan to purchase a trove of antibody-related assets from Atreca, Inc. (Nasdaq: BCEL). This move underscores Immunome’s strategic commitment to pioneering innovations in the field of cancer treatment.
Clay B. Siegall, Ph.D., Chairman and Chief Executive Officer of Immunome, expressed his belief that the acquisition of these novel and underexplored targets will be instrumental in driving the next generation of transformative Antibody Drug Conjugates (ADCs). “These antibody-related assets will expand our toolbox, complementing our existing programs as we advance our mission of developing innovative treatments for cancer patients,” he stated.
While the terms of the asset purchase agreement include a $5.5 million upfront payment from Immunome to Atreca, there is also a provision for up to $7.0 million in clinical development milestones. The completion of this transaction hinges on customary conditions, notably the need for Atreca to secure a required stockholder vote.
Immunome has built a reputation as a trailblazer in the biotech sector with its focus on developing first-in-class and best-in-class targeted cancer therapies. The company’s diverse portfolio includes immunotherapies, targeted effectors, radioligand therapies, and ADCs, each designed to tackle specific target biology.
The Exton, Pennsylvania-based company strongly believes that the pursuit of underexplored targets with the right drug modalities can lead to transformative therapies. To this end, Immunome has developed a proprietary memory B cell hybridoma technology that enables rapid screening and functional characterization of novel antibodies and targets.
This deal between Immunome and Atreca represents a significant step in the biotech sector, with potential implications for the future of cancer therapy. As Immunome continues to expand its arsenal of tools and technologies, investors and stakeholders alike will be watching with keen interest as the company forges ahead in its mission to transform the landscape of cancer treatment.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.